As shown in Figure 4A–C, the anti-PD-L1 antibody combined with regorafenib plus chidamide-k30 regimen more effectively inhibited tumor growth than the anti-CTLA-4 or anti-PD-1 antibody combination regimens. Here, CTLA4 is linked to neoplasm.